Chronic inflammation and cancer: Potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism

Journal of Inflammation (United Kingdom)

Volumn 11, Issue 1, 2014, Pages

  Pal, Srabani ^a   Bhattacharjee, Ashish ^b   Ali, Asif ^d   Mandal, Narayan C ^c   Mandal, Subhash C ^a   Pal, Mahadeb ^d  

^a JADAVPUR UNIVERSITY   (India)

^b NATIONAL INSTITUTE OF TECHNOLOGY   (India)

^c VISVA BHARATI UNIVERSITY   (India)

^d BOSE INSTITUTE   (India)

Author keywords

Cancer; Chemoprevention; Inflammation; Inhibitor of kappaB kinase (IKK); Inhibitor of kB (I B); Lipopolysachharides (LPS); MDM2; Nuclear factor kappa B (NF B); Phytochemicals; Small molecule inhibitors; Toll like receptor (TLR); Tumor necrosis factor (TNF); Tumor suppressor p53 (TP53)

Indexed keywords

1 [5 HYDROXY 2 (2 THIENYL) 4 QUINAZOLINYLAMINO] 3 METHYL 2,5 PYRROLEDIONE; BORTEZOMIB; CARFILZOMIB; CURCUMIN; DELANZOMIB; FLAVOPIRIDOL; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; LENALIDOMIDE; MEPACRINE; MESALAZINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; NUTLIN 3; OPROZOMIB; POMALIDOMIDE; PROTEIN P53; RESVERATROL; ROSCOVITINE; SALAZOSULFAPYRIDINE; SALINOSPORAMIDE A; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; THALIDOMIDE; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC INFLAMMATION; DISEASE COURSE; DOWN REGULATION; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; GENE INDUCTION; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84906921942     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-11-23     Document Type: Review

References (410)

1. Modifiable risk factors for cancer. Stein CJ, Colditz GA, Br J Cancer 2004 90 299 303
2. Cancer is a preventable disease that requires major lifestyle changes. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB, Pharm Res 2008 25 2097 2116
3. Rossi AG, Sawatzky DA, The Resolution of Inflammation Birkhauser: Basel 2008
4. Inflammation and cancer: back to Virchow? Balkwill F, Mantovani A, Lancet 2001 357 539 545
5. Inflammation and cancer. Coussens LM, Werb Z, Nature 2002 420 860 867
6. Inflammation as a tumor promoter in cancer induction. Philip M, Rowley DA, Schreiber H, Semin Cancer Biol 2004 14 433 439
7. Monocyte adherence to human vascular endothelium. Beekhuizen H, van Furth R, J Leukoc Biol 1993 54 363 378
8. Rodent models of lymphocyte migration. Kulidjian AA, Inman R, Issekutz TB, Semin Immunol 1999 11 85 93
9. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. van Gils JM, Zwaginga JJ, Hordijk PL, J Leukoc Biol 2009 85 195 204
10. Inflammation in wound repair: molecular and cellular mechanisms. Eming SA, Krieg T, Davidson JM, J Invest Dermatol 2007 127 514 525
11. Tissue destruction by neutrophils. Weiss SJ, N Engl J Med 1989 320 365 376
12. Cancer: an inflammatory link. Balkwill F, Coussens LM, Nature 2004 431 405 406
13. Regulatory role of endogenous interleukin-10 in cutaneous inflammatory response of murine wound healing. Sato Y, Ohshima T, Kondo T, Biochem Biophys Res Commun 1999 265 194 199
14. Roles for inflammation and regulatory T cells in colon cancer. Erdman SE, Poutahidis T, Toxicol Pathol 2010 38 76 87
15. Interleukin-10-deficient mice develop chronic enterocolitis. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W, Cell 1993 75 263 274
16. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Mhawech P, Staudt LM, Schwaller J, Blood 2005 105 2891 2899
17. Interleukin-10 and the interleukin-10 receptor. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A, Annu Rev Immunol 2001 19 683 765
18. Intestinal inflammation and colorectal cancer: a double-edged sword? Rizzo A, Pallone F, Monteleone G, Fantini MC, World J Gastroenterol 2011 17 3092 3100
19. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr, J Biol Chem 1999 274 31868 31874
20. Molecular pathways linking inflammation and cancer. Mantovani A, Curr Mol Med 2010 10 369 373
21. Deubiquitinases in the regulation of NF-kappaB signaling. Harhaj EW, Dixit VM, Cell Res 2012 21 22 39
22. Paradoxical roles of the immune system during cancer development. de Visser KE, Eichten A, Coussens LM, Nat Rev Cancer 2006 6 24 37
23. A cytokine-mediated link between innate immunity, inflammation, and cancer. Lin WW, Karin M, J Clin Invest 2007 117 1175 1183
24. Infections as a major preventable cause of human cancer. Kuper H, Adami HO, Trichopoulos D, J Intern Med 2000 248 171 183
25. Intestinal carcinogenesis: IKK can go all the way. Sunami Y, Wirth T, J Clin Invest 2011 121 2551 2553
26. Oxidants and signaling by mitogen-activated protein kinases in lung epithelium. Mossman BT, Lounsbury KM, Reddy SP, Am J Respir Cell Mol Biol 2006 34 666 669
27. Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review). Vaid M, Katiyar SK, Int J Oncol 2010 36 1053 1060
28. Hepatocellular carcinoma-epidemiological trends and risk factors. Schutte K, Bornschein J, Malfertheiner P, Dig Dis 2009 27 80 92
29. Chronic inflammation, immune escape and oncogenesis in the liver: a unique neighborhood for novel intersections. Stauffer JK, Scarzello AJ, Jiang Q, Wiltrout RH, Hepatology 2012 56 4 1567 1574
30. Helicobacter pylori and gastric carcinoma. Loffeld RJ, Willems I, Flendrig JA, Arends JW, Histopathology 1990 17 537 541
31. Helicobacter pylori gastritis and gastric MALT-lymphoma. Stolte M, Lancet 1992 339 745 746
32. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Ernst PB, Gold BD, Annu Rev Microbiol 2000 54 615 640
33. Chronic inflammation and cancer. Shacter E, Weitzman SA, Oncology (Williston Park) 2002 16 217 226, 229; discussion 230-212
34. Acid reflux and oesophageal cancer. Nicholson A, Jankowski J, Recent Results Cancer Res 2011 185 65 82
35. Schistosomiasis. Gryseels B, Infect Dis Clin North Am 2012 26 383 397
36. The global health burden of infection-associated cancers in the year 2002. Parkin DM, Int J Cancer 2006 118 3030 3044
37. Parasites and poverty: the case of schistosomiasis. King CH, Acta Trop 2010 113 95 104
38. Helminths in the induction of cancer: Opisthorchis viverrini, Clonorchis sinensis and cholangiocarcinoma. Schwartz DA, Trop Geogr Med 1980 32 95 100
39. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Abraham C, Medzhitov R, Gastroenterology 2011 140 1729 1737
40. 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Clapper ML, Gary MA, Coudry RA, Litwin S, Chang WC, Devarajan K, Lubet RA, Cooper HS, Inflamm Bowel Dis 2008 14 1341 1347
41. Infections and cancer: established associations and new hypotheses. de Martel C, Franceschi S, Crit Rev Oncol Hematol 2009 70 183 194
42. Liver cancer and alcohol. Grewal P, Viswanathen VA, Clin Liver Dis 2012 16 839 850
43. Infection, immunoregulation, and cancer. Rook GA, Dalgleish A, Immunol Rev 240 141 159
44. Inflammation in alcoholic liver disease. Wang HJ, Gao B, Zakhari S, Nagy LE, Annu Rev Nutr 2012 32 343 368
45. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM, Cell 1990 63 1129 1136
46. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB, J Clin Invest 1997 100 3019 3026
47. Spectrum of Epstein-Barr virus-associated diseases. Kutok JL, Wang F, Annu Rev Pathol 2006 1 375 404
48. The experimental disclosure of latent neoplastic changes in tarred skin. Mackenzie I, Rous P, J Exp Med 1941 73 391 416
49. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Balkwill F, Charles KA, Mantovani A, Cancer Cell 2005 7 211 217
50. Antibiotic use in relation to the risk of breast cancer. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH, JAMA 2004 291 827 835
51. Tetracycline up-regulates COX-2 expression and prostaglandin E2 production independent of its effect on nitric oxide. Attur MG, Patel RN, Patel PD, Abramson SB, Amin AR, J Immunol 1999 162 3160 3167
52. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. Enzler T, Gillessen S, Manis JP, Ferguson D, Fleming J, Alt FW, Mihm M, Dranoff G, J Exp Med 2003 197 1213 1219
53. Missing pieces in the NF-kappaB puzzle. Ghosh S, Karin M, Cell 2002 109 Suppl 81 S96
54. Celebrating 25 years of NF-kappaB research. Ghosh S, Hayden MS, Immunol Rev 2012 246 5 13
55. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Sen R, Baltimore D, Cell 1986 47 921 928
56. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Karin M, Ben-Neriah Y, Annu Rev Immunol 2000 18 621 663
57. Regulation and function of NF-kappaB transcription factors in the immune system. Vallabhapurapu S, Karin M, Annu Rev Immunol 2009 27 693 733
58. The IKK NF-kappa B system: a treasure trove for drug development. Karin M, Yamamoto Y, Wang QM, Nat Rev Drug Discov 2004 3 17 26
59. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Zhong H, May MJ, Jimi E, Ghosh S, Mol Cell 2002 9 625 636
60. The Rel family member P50 mediates cytokine-induced C-reactive protein expression by a novel mechanism. Cha-Molstad H, Agrawal A, Zhang D, Samols D, Kushner I, J Immunol 2000 165 4592 4597
61. Oncogenes, tumor suppressors and p52 NF-kappaB. Perkins ND, Oncogene 2003 22 7553 7556
62. Pathogen recognition by innate immunity and its signaling. Akira S, Proc Jpn Acad Ser B Phys Biol Sci 2009 85 143 156
63. Toll-like receptors and innate immunity. Medzhitov R, Nat Rev Immunol 2001 1 135 145
64. CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. Girardin SE, Tournebize R, Mavris M, Page AL, Li X, Stark GR, Bertin J, DiStefano PS, Yaniv M, Sansonetti PJ, Philpott DJ, EMBO Rep 2001 2 736 742
65. Signaling in innate immunity and inflammation. Newton K, Dixit VM, Cold Spring Harb Perspect Biol 2012 4 1 19
66. Invasive Shigella flexneri activates NF-kappa B through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells. Philpott DJ, Yamaoka S, Israel A, Sansonetti PJ, J Immunol 2000 165 903 914
67. Nod-like receptors in intestinal host defense: controlling pathogens, the microbiota, or both? Robertson SJ, Girardin SE, Curr Opin Gastroenterol 2012 29 15 22
68. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-{kappa}B activation in muramyl dipeptide recognition. Barnich N, Aguirre JE, Reinecker HC, Xavier R, Podolsky DK, J Cell Biol 2005 170 21 26
69. Nod-like proteins in immunity, inflammation and disease. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE, Nat Immunol 2006 7 1250 1257
70. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Sancho D, Reis ESC, Annu Rev Immunol 2012 30 491 529
71. The TREM receptor family and signal integration. Klesney-Tait J, Turnbull IR, Colonna M, Nat Immunol 2006 7 1266 1273
72. TREM-1: intracellular signaling pathways and interaction with pattern recognition receptors. Arts RJ, Joosten LA, van der Meer JW, Netea MG, J Leukoc Biol 2012 93 209 215
73. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. Bouchon A, Dietrich J, Colonna M, J Immunol 2000 164 4991 4995
74. TREM and TREM-like receptors in inflammation and disease. Ford JW, McVicar DW, Curr Opin Immunol 2009 21 38 46
75. The IKK complex, a central regulator of NF-kappaB activation. Israel A, Cold Spring Harb Perspect Biol 2010 2.000158
76. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K, Nature 1999 398 252 256
77. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ, Nature 2001 412 346 351
78. TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. Takaesu G, Surabhi RM, Park KJ, Ninomiya-Tsuji J, Matsumoto K, Gaynor RB, J Mol Biol 2003 326 105 115
79. TAK1 mediates an activation signal from toll-like receptor(s) to nuclear factor-kappaB in lipopolysaccharide-stimulated macrophages. Irie T, Muta T, Takeshige K, FEBS Lett 2000 467 160 164
80. Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Huang Q, Yang J, Lin Y, Walker C, Cheng J, Liu ZG, Su B, Nat Immunol 2004 5 98 103
81. The essential role of MEKK3 in TNF-induced NF-kappaB activation. Yang J, Lin Y, Guo Z, Cheng J, Huang J, Deng L, Liao W, Chen Z, Liu Z, Su B, Nat Immunol 2001 2 620 624
82. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Delhase M, Hayakawa M, Chen Y, Karin M, Science 1999 284 309 313
83. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, Li ZW, Karin M, Ware CF, Green DR, Immunity 2002 17 525 535
84. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Senftleben U, Cao Y, Xiao G, Greten FR, Krähn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M, Science 2001 293 1495 1499
85. IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Sil AK, Maeda S, Sano Y, Roop DR, Karin M, Nature 2004 428 660 664
86. The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. Novack DV, Yin L, Hagen-Stapleton A, Schreiber RD, Goeddel DV, Ross FP, Teitelbaum SL, J Exp Med 2003 198 771 781
87. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M, Nature 1997 388 548 554
88. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Rothwarf DM, Zandi E, Natoli G, Karin M, Nature 1998 395 297 300
89. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M, Cell 1997 91 243 252
90. IKK biology. Liu F, Xia Y, Parker AS, Verma IM, Immunol Rev 2012 246 239 253
91. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T, Genes Dev 1995 9 1586 1597
92. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, Rao A, Science 1997 278 860 866
93. Regulation of NF-kappaB by ubiquitination and degradation of the IkappaBs. Kanarek N, Ben-Neriah Y, Immunol Rev 2012 246 77 94
94. Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase. Yaron A, Gonen H, Alkalay I, Hatzubai A, Jung S, Beyth S, Mercurio F, Manning AM, Ciechanover A, Ben-Neriah Y, EMBO J 1997 16 6486 6494
95. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F, Ben-Neriah Y, Nature 1998 396 590 594
96. NF-kappaB regulation: lessons from structures. Ghosh G, Wang VY, Huang DB, Fusco A, Immunol Rev 2012 246 36 58
97. The atypical PKCs in inflammation: NF-kappaB and beyond. Diaz-Meco MT, Moscat J, Immunol Rev 2012 246 154 167
98. Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal. Ghosh S, Gifford AM, Riviere LR, Tempst P, Nolan GP, Baltimore D, Cell 1990 62 1019 1029
99. NF-kappa B, KBF1, dorsal, and related matters. Gilmore TD, Cell 1990 62 841 843
100. NF-kappaB: linking inflammation and immunity to cancer development and progression. Karin M, Greten FR, Nat Rev Immunol 2005 5 749 759
101. Inflammation and cancer: how friendly is the relationship for cancer patients? Aggarwal BB, Gehlot P, Curr Opin Pharmacol 2009 9 351 369
102. Oncogenic activation of NF-kappaB. Staudt LM, Cold Spring Harb Perspect Biol 2010 2.000109
103. Curaxins: anticancer compounds that simultaneously suppress NF-kappaB and activate p53 by targeting FACT. Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA, Pal S, Safina A, Sviridov S, Koman IE, Veith J, Komar AA, Gudkov AV, Gurova KV, Sci Transl Med 2011 3 95ra74
104. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV, Proc Natl Acad Sci U S A 2005 102 17448 17453
105. Constitutive IKK2 activation in intestinal epithelial cells induces intestinal tumors in mice. Vlantis K, Wullaert A, Sasaki Y, Schmidt-Supprian M, Rajewsky K, Roskams T, Pasparakis M, J Clin Invest 2011 121 2781 2793
106. Peptides genetically selected for NF-kappaB activation cooperate with oncogene Ras and model carcinogenic role of inflammation. Natarajan V, Komarov AP, Ippolito T, Bonneau K, Chenchik AA, Gudkov AV, Proc Natl Acad Sci U S A 2014 111 474 E483
107. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Sun J, Wiklund F, Hsu FC, Bälter K, Zheng SL, Johansson JE, Chang B, Liu W, Li T, Turner AR, Li L, Li G, Adami HO, Isaacs WB, Xu J, Grönberg H, Cancer Epidemiol Biomarkers Prev 2006 15 480 485
108. The application of Toll like receptors for cancer therapy. So EY, Ouchi T, Int J Biol Sci 2010 6 675 681
109. Toll-like receptors expressed in tumor cells: targets for therapy. Yu L, Chen S, Cancer Immunol Immunother 2008 57 1271 1278
110. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT, Gastroenterology 2007 133 1869 1881
111. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Wolska A, Lech-Maranda E, Robak T, Cell Mol Biol Lett 2009 14 248 272
112. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, et al. Nat Genet 2008 40 955 962
113. [Role of NOD2 gene in Crohn's disease]. Hugot JP, Gastroenterol Clin Biol 2002 26 13 15
114. Unravelling the pathogenesis of inflammatory bowel disease. Xavier RJ, Podolsky DK, Nature 2007 448 427 434
115. NOD2 and Crohn's disease: loss or gain of function? Eckmann L, Karin M, Immunity 2005 22 661 667
116. Polymorphism of IL-1 receptor antagonist gene: role in cancer. Sehouli J, Mustea A, Konsgen D, Katsares I, Lichtenegger W, Anticancer Res 2002 22 3421 3424
117. The role of interleukin-1beta and other potential genetic markers as indicators of gastric cancer risk. Troost E, Hold GL, Smith MG, Chow WH, Rabkin CS, McColl KE, El-Omar EM, Can J Gastroenterol 2003 17 Suppl B 8B 12B
118. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E, Cancer Metastasis Rev 2006 25 387 408
119. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. Lewis AM, Varghese S, Xu H, Alexander HR, J Transl Med 2006 4 48
120. The nuclear factor NF-kappaB pathway in inflammation. Lawrence T, Cold Spring Harb Perspect Biol 2009 1.001651
121. NF-kappaB and cancer: how intimate is this relationship. Prasad S, Ravindran J, Aggarwal BB, Mol Cell Biochem 2010 336 25 37
122. APC, signal transduction and genetic instability in colorectal cancer. Fodde R, Smits R, Clevers H, Nat Rev Cancer 2001 1 55 67
123. MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S, Kufe D, Nat Cell Biol 2007 9 1419 1427
124. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM, Science 2008 319 1676 1679
125. Constitutive activation of NF-kappa B is essential for transformation of rat fibroblasts by the human T-cell leukemia virus type I Tax protein. Yamaoka S, Inoue H, Sakurai M, Sugiyama T, Hazama M, Yamada T, Hatanaka M, EMBO J 1996 15 873 887
126. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Wood KM, Roff M, Hay RT, Oncogene 1998 16 2131 2139
127. Biological and therapeutic significance of tissue transglutaminase in pancreatic cancer. Mehta K, Amino Acids 2009 36 709 716
128. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal BB, Mehta K, Cancer Res 2006 66 8788 8795
129. Inflammation and p53: a tale of two stresses. Gudkov AV, Gurova KV, Komarova EA, Genes Cancer 2011 2 503 516
130. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Vucic D, Dixit VM, Wertz IE, Nat Rev Mol Cell Biol 2011 12 439 452
131. Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Huang WC, Ju TK, Hung MC, Chen CC, Mol Cell 2007 26 75 87
132. PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. Mayo MW, Madrid LV, Westerheide SD, Jones DR, Yuan XJ, Baldwin ASJr., Whang YE, J Biol Chem 2002 277 11116 11125
133. The diverse and complex roles of NF-kappaB subunits in cancer. Perkins ND, Nat Rev Cancer 2012 12 121 132
134. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Rocha S, Campbell KJ, Perkins ND, Mol Cell 2003 12 15 25
135. INK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappaB. Wolff B, Naumann M, Oncogene 1999 18 2663 2666
136. CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappaB. Kashima L, Toyota M, Mita H, Suzuki H, Idogawa M, Ogi K, Sasaki Y, Tokino T, Oncogene 2009 28 2643 2653
137. TCEAL7, a putative tumor suppressor gene, negatively regulates NF-kappaB pathway. Rattan R, Narita K, Chien J, Maguire JL, Shridhar R, Giri S, Shridhar V, Oncogene 2010 29 1362 1373
138. LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Wang J, An H, Mayo MW, Baldwin AS, Yarbrough WG, Cancer Cell 2007 12 239 251
139. ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters. Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Levrero M, Strano S, Rotter V, Oren M, Blandino G, OMICS 2011 15 305 312
140. Pathologies associated with the p53 response. Gudkov AV, Komarova EA, Cold Spring Harb Perspect Biol 2010 2.001180
141. A complex barcode underlies the heterogeneous response of p53 to stress. Murray-Zmijewski F, Slee EA, Lu X, Nat Rev Mol Cell Biol 2008 9 702 712
142. p53 and NF-kappaB: different strategies for responding to stress lead to a functional antagonism. Ak P, Levine AJ, FASEB J 2010 24 3643 3652
143. The regulation of multiple p53 stress responses is mediated through MDM2. Hu W, Feng Z, Levine AJ, Genes Cancer 2012 3 199 208
144. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Huang L, Yan Z, Liao X, Li Y, Yang J, Wang ZG, Zuo Y, Kawai H, Shadfan M, Ganapathy S, Yuan ZM, Proc Natl Acad Sci U S A 2011 108 12001 12006
145. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Pant V, Xiong S, Iwakuma T, Quintas-Cardama A, Lozano G, Proc Natl Acad Sci U S A 2011 108 11995 12000
146. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Wade M, Li YC, Wahl GM, Nat Rev Cancer 2013 13 83 96
147. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Mayo LD, Turchi JJ, Berberich SJ, Cancer Res 1997 57 5013 5016
148. c-Abl phosphorylates Hdmx and regulates its interaction with p53. Zuckerman V, Lenos K, Popowicz GM, Silberman I, Grossman T, Marine JC, Holak TA, Jochemsen AG, Haupt Y, J Biol Chem 2009 284 4031 4039
149. Repression of p53-mediated transcription by MDM2: a dual mechanism. Thut CJ, Goodrich JA, Tjian R, Genes Dev 1997 11 1974 1986
150. The regulation of MDM2 by multisite phosphorylation-opportunities for molecular-based intervention to target tumours? Meek DW, Hupp TR, Semin Cancer Biol 2010 20 19 28
151. Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding. Lopez-Pajares V, Kim MM, Yuan ZM, J Biol Chem 2008 283 13707 13713
152. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Mayo LD, Donner DB, Proc Natl Acad Sci U S A 2001 98 11598 11603
153. Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity. Goh AM, Lim CY, Chiam PC, Li L, Mann MB, Mann KM, Menendez S, Lane DP, Proc Natl Acad Sci U S A 2012 109 1685 1690
154. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Toledo F, Wahl GM, Nat Rev Cancer 2006 6 909 923
155. Tissue-specific induction of p53 targets in vivo. Fei P, Bernhard EJ, El-Deiry WS, Cancer Res 2002 62 7316 7327
156. How p53 wields the scales of fate: arrest or death? Goh AM, Lane DP, Transcription 2012 3 240 244
157. Drugging the p53 pathway: understanding the route to clinical efficacy. Khoo KH, Verma CS, Lane DP, Nat Rev Drug Discov 2014 13 217 236
158. Regulation of p53 downstream genes. el-Deiry WS, Semin Cancer Biol 1998 8 345 357
159. Definition of a consensus binding site for p53. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B, Nat Genet 1992 1 45 49
160. Cell cycle. Piwnica-Worms H, Fools Rush Nature 1999 401 535, 537
161. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. St Clair S, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu WJ, Padi A, Dastidar J, DaCosta A, Mattia M, Manfredi JJ, Mol Cell 2004 16 725 736
162. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J, Proc Natl Acad Sci U S A 1992 89 4495 4499
163. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Kortlever RM, Higgins PJ, Bernards R, Nat Cell Biol 2006 8 877 884
164. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M, Nature 1991 352 345 347
165. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T, Ryan KM, Cell 2006 126 121 134
166. Transcriptional regulation by p53. Beckerman R, Prives C, Cold Spring Harb Perspect Biol 2010 2.000935
167. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Gurova K, Future Oncol 2009 5 1685 1704
168. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Kashatus D, Cogswell P, Baldwin AS, Genes Dev 2006 20 225 235
169. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I, Cancer Cell 2002 1 493 503
170. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME, Cell 1997 91 231 241
171. The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Jiang P, Du W, Heese K, Wu M, Mol Cell Biol 2006 26 9071 9082
172. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Vivanco I, Sawyers CL, Nat Rev Cancer 2002 2 489 501
173. Akt is more than just a Bad kinase. Khwaja A, Nature 1999 401 33 34
174. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Romashkova JA, Makarov SS, Nature 1999 401 86 90
175. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB, Nature 1999 401 82 85
176. Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Xia Y, Padre RC, De Mendoza TH, Bottero V, Tergaonkar VB, Verma IM, Proc Natl Acad Sci U S A 2009 106 2629 2634
177. Tumor suppression by Ink4a-Arf: progress and puzzles. Lowe SW, Sherr CJ, Curr Opin Genet Dev 2003 13 77 83
178. ARF the integrator: linking NF-kappaB, p53 and checkpoint kinases. Rocha S, Perkins ND, Cell Cycle 2005 4 756 759
179. Integrating cell-signalling pathways with NF-kappaB and IKK function. Perkins ND, Nat Rev Mol Cell Biol 2007 8 49 62
180. p300/CBP-dependent and -independent transcriptional interference between NF-kappaB RelA and p53. Ikeda A, Sun X, Li Y, Zhang Y, Eckner R, Doi TS, Takahashi T, Obata Y, Yoshioka K, Yamamoto K, Biochem Biophys Res Commun 2000 272 375 379
181. Recruitment of p300/CBP in p53-dependent signal pathways. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K, Cell 1997 89 1175 1184
182. CREB-binding protein/p300 are transcriptional coactivators of p65. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T, Proc Natl Acad Sci U S A 1997 94 2927 2932
183. Transcriptional cross talk between NF-kappaB and p53. Webster GA, Perkins ND, Mol Cell Biol 1999 19 3485 3495
184. p53 and NF-kappaB crosstalk: IKKalpha tips the balance. Tergaonkar V, Perkins ND, Mol Cell 2007 26 158 159
185. Activated p53 induces NF-kappaB DNA binding but suppresses its transcriptional activation. Kawauchi K, Araki K, Tobiume K, Tanaka N, Biochem Biophys Res Commun 2008 372 137 141
186. Loss of p53 enhances NF-kappaB-dependent lamellipodia formation. Guo AK, Hou YY, Hirata H, Yamauchi S, Yip AK, Chiam KH, Tanaka N, Sawada Y, Kawauchi K, J Cell Physiol 2014 229 696 704
187. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Kawauchi K, Araki K, Tobiume K, Tanaka N, Nat Cell Biol 2008 10 611 618
188. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E, Cancer Res 2004 64 2627 2633
189. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH, Cell 2006 126 107 120
190. p53 regulates mitochondrial respiration. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM, Science 2006 312 1650 1653
191. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CAJr., Butel JS, Bradley A, Nature 1992 356 215 221
192. p53 is a suppressor of inflammatory response in mice. Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, Brennan ML, Golovkina TV, Rokhlin OW, Kuprash DV, Nedospasov SA, Hazen SL, Feinstein E, Gudkov AV, FASEB J 2005 19 1030 1032
193. Drugs: more shots on target. Appel A, Nature 2011 480 40 S42
194. Inhibitors of NF-kappaB signaling: 785 and counting. Gilmore TD, Herscovitch M, Oncogene 2006 25 6887 6899
195. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y, Proc Natl Acad Sci U S A 1995 92 10599 10603
196. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE, Cancer Res 2007 67 1783 1792
197. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Kane RC, Bross PF, Farrell AT, Pazdur R, Oncologist 2003 8 508 513
198. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Kane RC, Farrell AT, Sridhara R, Pazdur R, Clin Cancer Res 2006 12 2955 2960
199. Novel proteasome inhibitors to overcome bortezomib resistance. Ruschak AM, Slassi M, Kay LE, Schimmer AD, J Natl Cancer Inst 2011 103 1007 1017
200. NF-kappaB and the link between inflammation and cancer. DiDonato JA, Mercurio F, Karin M, Immunol Rev 2012 246 379 400
201. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M, Science 2006 314 467 471
202. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY, Lee DF, Liu JC, Zhong Q, Wang X, Hung MC, Mol Cell Biol 2007 27 4006 4017
203. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, Hershko A, Pagano M, Draetta GF, Nature 2003 426 87 91
204. Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Kanemori Y, Uto K, Sagata N, Proc Natl Acad Sci U S A 2005 102 6279 6284
205. HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin. Fuchs SY, Chen A, Xiong Y, Pan ZQ, Ronai Z, Oncogene 1999 18 2039 2046
206. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, Hattori K, Nakamichi I, Kikuchi A, Nakayama K, EMBO J 1999 18 2401 2410
207. Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold JH, Post S, Jansen A, Colburn NH, Allgayer H, Cancer 2007 110 1697 1707
208. A novel small-molecule inhibitor of NF-kappaB signaling. Nakajima H, Fujiwara H, Furuichi Y, Tanaka K, Shimbara N, Biochem Biophys Res Commun 2008 368 1007 1013
209. Inhibition of TNF-alpha-induced NF-kappaB activation and IL-8 release in A549 cells with the proteasome inhibitor MG-132. Fiedler MA, Wernke-Dollries K, Stark JM, Am J Respir Cell Mol Biol 1998 9 259 268
210. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J, Qiu Y, Zusi FC, J Biol Chem 2003 278 1450 1456
211. Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents. Murata T, Shimada M, Sakakibara S, Yoshino T, Masuda T, Shintani T, Sato H, Koriyama Y, Fukushima K, Nunami N, Yamauchi M, Fuchikami K, Komura H, Watanabe A, Ziegelbauer KB, Bacon KB, Lowinger TB, Bioorg Med Chem Lett 2004 14 4019 4022
212. Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-kappaB1 DNA binding domain. Lambert C, Li J, Jonscher K, Yang TC, Reigan P, Quintana M, Harvey J, Freed BM, J Biol Chem 2007 282 19666 19675
213. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB, Mol Cancer Ther 2006 5 3232 3239
214. Dihydroxyphenylethanol induces apoptosis by activating serine/threonine protein phosphatase PP2A and promotes the endoplasmic reticulum stress response in human colon carcinoma cells. Guichard C, Pedruzzi E, Fay M, Marie JC, Braut-Boucher F, Daniel F, Grodet A, Gougerot-Pocidalo MA, Chastre E, Kotelevets L, Lizard G, Vandewalle A, Driss F, Ogier-Denis E, Carcinogenesis 2006 27 1812 1827
215. Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. Nagashima K, Sasseville VG, Wen D, Bielecki A, Yang H, Simpson C, Grant E, Hepperle M, Harriman G, Jaffee B, Ocain T, Xu Y, Fraser CC, Blood 2006 107 4266 4273
216. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, Hauser S, Huynh K, Bonar S, Mielke C, Albee L, Weier R, Graneto M, Hanau C, Perry T, Tripp CS, J Biol Chem 2003 278 32861 32871
217. Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. Morwick T, Berry A, Brickwood J, Cardozo M, Catron K, DeTuri M, Emeigh J, Homon C, Hrapchak M, Jacober S, Jakes S, Kaplita P, Kelly TA, Ksiazek J, Liuzzi M, Magolda R, Mao C, Marshall D, McNeil D, Prokopowicz A3rd, Sarko C, Scouten E, Sledziona C, Sun S, Watrous J, Wu JP, Cywin CL, J Med Chem 2006 49 2898 2908
218. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. Pandey MK, Sandur SK, Sung B, Sethi G, Kunnumakkara AB, Aggarwal BB, J Biol Chem 2007 282 17340 17350
219. beta-Carboline alkaloid suppresses NF-kappaB transcriptional activity through inhibition of IKK signaling pathway. Yoon JW, Kang JK, Lee KR, Lee HW, Han JW, Seo DW, Kim YK, J Toxicol Environ Health A 2005 68 2005 2017
220. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB, Cancer Res 2008 68 5370 5379
221. A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. Inayama M, Nishioka Y, Azuma M, Muto S, Aono Y, Makino H, Tani K, Uehara H, Izumi K, Itai A, Sone S, Am J Respir Crit Care Med 2006 173 1016 1022
222. Novel IKK inhibitors: beta-carbolines. Castro AC, Dang LC, Soucy F, Grenier L, Mazdiyasni H, Hottelet M, Parent L, Pien C, Palombella V, Adams J, Bioorg Med Chem Lett 2003 13 2419 2422
223. 17-Acetoxyjolkinolide B irreversibly inhibits IkappaB kinase and induces apoptosis of tumor cells. Yan SS, Li Y, Wang Y, Shen SS, Gu Y, Wang HB, Qin GW, Yu Q, Mol Cancer Ther 2008 7 1523 1532
224. CML-1 inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in endothelial cells through inhibition of IkBalpha kinase. Mo SJ, Son EW, Lee SR, Lee SM, Shin DH, Pyo S, J Ethnopharmacol 2007 109 78 86
225. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, Hong YS, Lee JJ, Biochem Pharmacol 2006 72 1311 1321
226. Suppression of interleukin-6 production in macrophages by furonaphthoquinone NFD-37. Shin HM, Lee YR, Chang YS, Lee JY, Kim BH, Min KR, Kim Y, Int Immunopharmacol 2006 6 916 923
227. 3-Formylchromone interacts with cysteine 38 in p65 protein and with cysteine 179 in IkappaBalpha kinase, leading to down-regulation of nuclear factor-kappaB (NF-kappaB)-regulated gene products and sensitization of tumor cells. Yadav VR, Prasad S, Gupta SC, Sung B, Phatak SS, Zhang S, Aggarwal BB, J Biol Chem 2011 287 245 256
228. Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Catley MC, Sukkar MB, Chung KF, Jaffee B, Liao SM, Coyle AJ, Haddad el B, Barnes PJ, Newton R, Mol Pharmacol 2006 70 697 705
229. Pinitol targets nuclear factor-kappaB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis. Sethi G, Ahn KS, Sung B, Aggarwal BB, Mol Cancer Ther 2008 7 1604 1614
230. PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-kappaB-dependent proinflammatory activation of alveolar epithelial cells. Callister ME, Pinhu L, Catley MC, Westwell AD, Newton R, Leaver SK, Quinlan GJ, Evans TW, Griffiths MJ, Burke-Gaffney A, Br J Pharmacol 2008 155 661 672
231. Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer. Kuefer R, Genze F, Zugmaier W, Hautmann RE, Rinnab L, Gschwend JE, Angelmeier M, Estrada A, Buechele B, Neoplasia 2007 9 246 253
232. Inhibitors of NF-kappaB derived from thalidomide. de-Blanco EJ, Pandit B, Hu Z, Shi J, Lewis A, Li PK, Bioorg Med Chem Lett 2007 17 6031 6035
233. Salubrinal attenuates beta-amyloid-induced neuronal death and microglial activation by inhibition of the NF-kappaB pathway. Neurobiol Aging. Huang X, Chen Y, Zhang H, Ma Q, Zhang YW, Xu H, 2011 1007 33 1009 1017
234. Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation. Syed DN, Afaq F, Sarfaraz S, Khan N, Kedlaya R, Setaluri V, Mukhtar H, Toxicol Appl Pharmacol 2008 231 52 60
235. Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: therapeutic implications for the treatment of atherosclerosis? Jagielska J, Salguero G, Schieffer B, Bavendiek U, Atherosclerosis 2009 206 390 396
236. Dihydrotestosterone inhibits interleukin-1alpha or tumor necrosis factor alpha-induced proinflammatory cytokine production via androgen receptor-dependent inhibition of nuclear factor-kappaB activation in rheumatoid fibroblast-like synovial cell line. Xu J, Itoh Y, Hayashi H, Takii T, Miyazawa K, Onozaki K, Biol Pharm Bull 2011 34 1724 1730
237. Down-regulation of iNOS and TNF-alpha expression by kaempferol via NF-kappaB inactivation in aged rat gingival tissues. Kim HK, Park HR, Lee JS, Chung TS, Chung HY, Chung J, Biogerontology 2007 8 399 408
238. Tomatidine inhibits iNOS and COX-2 through suppression of NF-kappaB and JNK pathways in LPS-stimulated mouse macrophages. Chiu FL, Lin JK, FEBS Lett 2008 582 2407 2412
239. Anti-inflammatory effect of allylpyrocatechol in LPS-induced macrophages is mediated by suppression of iNOS and COX-2 via the NF-kappaB pathway. Sarkar D, Saha P, Gamre S, Bhattacharjee S, Hariharan C, Ganguly S, Sen R, Mandal G, Chattopadhyay S, Majumdar S, Chatterjee M, Int Immunopharmacol 2008 8 1264 1271
240. Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Hwang J, Zheng LT, Ock J, Lee MG, Kim SH, Lee HW, Lee WH, Park HC, Suk K, Neuropharmacology 2008 55 826 834
241. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factor-kappaB signaling. Rajapakse N, Kim MM, Mendis E, Kim SK, Immunology 2008 123 348 357
242. Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats. Zhu WW, Liu XP, Wu N, Zhao TT, Zhao Y, Zhang J, Shao JH, Mol Cell Biochem 2007 304 35 43
243. Metformin inhibits P-glycoprotein expression via the NF-kappaB pathway and CRE transcriptional activity through AMPK activation. Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, Kang KW, Kwon KI, Kim BH, Kim SK, Song GY, Jeong TC, Jeong HG, Br J Pharmacol 2008 162 1096 1108
244. Sevoflurane and isoflurane decrease TNF-alpha-induced gene expression in human monocytic THP-1 cells: potential role of intracellular IkappaBalpha regulation. Boost KA, Leipold T, Scheiermann P, Hoegl S, Sadik CD, Hofstetter C, Zwissler B, Int J Mol Med 2009 23 665 671
245. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Dey A, Wong ET, Cheok CF, Tergaonkar V, Lane DP, Cell Death Differ 2008 15 263 273
246. Synthesis and biological evaluation of guanidino analogues of roscovitine. Doleckova I, Cesnek M, Dracinsky M, Brynda J, Voller J, Janeba Z, Krystof V, Eur J Med Chem 2013 62 443 452
247. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Lu W, Chen L, Peng Y, Chen J, Oncogene 2001 20 3206 3216
248. Identification of HEXIM1 as a positive regulator of p53. Lew QJ, Chia YL, Chu KL, Lam YT, Gurumurthy M, Xu S, Lam KP, Cheong N, Chao SH, J Biol Chem 2012 287 36443 36454
249. Controlling the elongation phase of transcription with P-TEFb. Peterlin BM, Price DH, Mol Cell 2006 23 297 305
250. Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. Takada Y, Aggarwal BB, J Biol Chem 2004 279 4750 4759
251. Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Dey A, Wong ET, Bist P, Tergaonkar V, Lane DP, Cell Cycle 2007 6 2178 2185
252. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA, Science 2004 303 844 848
253. Suppression of pro-inflammatory and proliferative pathways by diferuloylmethane (curcumin) and its analogues dibenzoylmethane, dibenzoylpropane, and dibenzylideneacetone: role of Michael acceptors and Michael donors. Anand P, Sung B, Kunnumakkara AB, Rajasekharan KN, Aggarwal BB, Biochem Pharmacol 2011 82 1901 1909
254. Multitargeting by curcumin as revealed by molecular interaction studies. Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, Aggarwal BB, Nat Prod Rep 2011 28 1937 1955
255. Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Harikumar KB, Kunnumakkara AB, Ahn KS, Anand P, Krishnan S, Guha S, Aggarwal BB, Blood 2009 113 2003 2013
256. Molecular mechanisms of curcumin action: signal transduction. Shehzad A, Lee YS, Biofactors 2013 39 27 36
257. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, Gurova KV, Oncogene 2009 28 1151 1161
258. Novel derivative of benzofuran induces cell death mostly by G2/M cell cycle arrest through p53-dependent pathway but partially by inhibition of NF-kappaB. Manna SK, Bose JS, Gangan V, Raviprakash N, Navaneetha T, Raghavendra PB, Babajan B, Kumar CS, Jain SK, J Biol Chem 2010 285 22318 22327
259. Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease. Lu C, Guo Y, Yan J, Luo Z, Luo HB, Yan M, Huang L, Li X, J Med Chem 2013 56 5843 5859
260. Sirtuins in mammals: insights into their biological function. Michan S, Sinclair D, Biochem J 2007 404 1 13
261. Sirtuins: critical regulators at the crossroads between cancer and aging. Saunders LR, Verdin E, Oncogene 2007 26 5489 5504
262. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW, EMBO J 2004 23 2369 2380
263. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, Greig NH, Mattson MP, J Neurochem 2001 77 220 228
264. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV, Science 1999 285 1733 1737
265. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP, Curr Cancer Drug Targets 2011 11 239 253
266. Ctk1 promotes dissociation of basal transcription factors from elongating RNA polymerase II. Ahn SH, Keogh MC, Buratowski S, EMBO J 2009 28 205 212
267. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ, Blood 2007 110 3281 3290
268. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Mujtaba T, Dou QP, Discov Med 2011 12 471 480
269. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC, Cancer Cell 2005 8 407 419
270. Proteasome structure, function, and lessons learned from beta-lactone inhibitors. Groll M, Potts BC, Curr Top Med Chem 2011 11 2850 2878
271. Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs. Obaidat A, Weiss J, Wahlgren B, Manam RR, Macherla VR, McArthur K, Chao TH, Palladino MA, Lloyd GK, Potts BC, Enna SJ, Neuteboom ST, Hagenbuch B, J Pharmacol Exp Ther 2011 337 479 486
272. McConkey: Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JCJr, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, Curr Cancer Drug Targets 2011 11 254 284
273. Clinical development of novel proteasome inhibitors for cancer treatment. Yang H, Zonder JA, Dou QP, Expert Opin Investig Drugs 2009 18 957 971
274. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC, Blood 2010 116 4906 4915
275. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Dick LR, Fleming PE, Drug Discov Today 2010 15 243 249
276. Proteasome inhibitors: an expanding army attacking a unique target. Kisselev AF, van der Linden WA, Overkleeft HS, Chem Biol 2012 19 99 115
277. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J, Cancer Res 2010 70 1970 1980
278. Thalidomide analogs as emerging anti-cancer drugs. Dredge K, Dalgleish AG, Marriott JB, Anticancer Drugs 2003 14 331 335
279. Inhibition of NF-B activity by thalidomide through suppression of IB kinase activity. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr, J Biol Chem 2001 276 22382 22387
280. Thalidomide suppresses NF- κ B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. Majumdar S, Lamothe B, Aggarwal BB, J Immunol 2002 168 2644 2651
281. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC, Blood 2002 99 4525 4530
282. Inducible cyclooxygenase may have antiinflammatory properties. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA, Nat Med 1999 5 698 701
283. The peroxisome proliferator-activated receptor- γ is a negative regulator of macrophage activation. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK, Nature 1998 391 79 82
284. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I κ B kinase. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG, Nature 2000 403 103 108
285. C/EBP{beta} and its binding element are required for NF{kappa}B-induced COX2 expression following hypertonic stress. Chen J, Zhao M, Rao R, Inoue H, Hao CM, J Biol Chem 2005 280 16354 16359
286. Identification of multiple cis-acting elements mediating the induction of prostaglandin G/H synthase-2 by phorbol ester in murine osteoblastic cells. Okada Y, Voznesensky O, Herschman H, Harrison J, Pilbeam C, J Cell Biochem 2000 78 197 209
287. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Tazawa R, Xu XM, Wu KK, Wang LH, Biochem Biophys Res Commun 1994 203 190 199
288. Sulindac inhibits activation of the NF-kappaB pathway. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB, J Biol Chem 1999 274 27307 27314
289. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Yin MJ, Yamamoto Y, Gaynor RB, Nature 1998 396 77 80
290. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T, J Immunol 1996 156 3961 3969
291. Sulfasalazine: A potent and specific inhibitor of NF-B. Wahl C, Liptay S, Adler G, Schmid RM, J Clin Invest 1997 101 1163 1174
292. Polk DB Aminosalicylic acid inhibits I κ B kinase- α phosphorylation of I κ B α in mouse intestinal epithelial cells. Yan F, J Biol Chem 1999 274 36631 36636
293. Inhibition of interleukin-1-stimulated NF- κ B RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, Lipsky JJ, McKean DJ, J Biol Chem 1999 274 26448 26453
294. Histone H3 phosphorylation by IKK- α is critical for cytokine-induced gene expression. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB, Nature 2003 423 655 659
295. IKK α provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, Karin M, Cell 2001 107 763 775
296. A nucleosomal function for I κ B kinase- α in NF- κ B-dependent gene expression. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS, Nature 2003 423 659 663
297. Quinazoline analogs and related compounds and methods for treating inflammatory conditions. Signal Pharmaceuticals, Inc, 1999 O 199901441
298. Identification of a disease modifying IKK2 inhibitor in rat adjuvant arthritis. Leisten JC, Grimshaw CE, Bennett B, Satoh Y, Xu W, O'Leary EC, Firestein GS, Boyle DL, Dreano M, Bhagwat SS, Ramon HK, Inflamm Res 2002 51 Suppl 2 25
299. Structure-activity relationship studies of ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: an inhibitor of AP-1 and NF- κ B mediated gene expression. Palanki MS, Gayo-Fung LM, Shevlin GI, Erdman P, Sato M, Goldman M, Ransone LJ, Spooner C, Bioorg Med Chem Lett 2002 12 2573 2577
300. Preparation of substituted carbolines as potential therapeutics in diseases associated with increased IB kinase activity. Adams J, Castro A, Grenier L, Hancock WW, Mazdiyasni H, Palombella V, Ritzeler O, Soucy F, Aventis Pharma Gmbh 2001. O 2001068648
301. NF- κ B as a therapeutic target in multiple myeloma. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC, J Biol Chem 2003 277 16639 16647
302. Method of treating inflammatory and immune diseases using 4-amino substituted imidazoquinoxaline, benzopyrazoloquinazoline, benzoimidazoquinoxaline and benzoimidazoquinoline inhibitors of IB kinase (IKK). Burke JR, Nadler S, Qiu Y, Townsend RM, Zusi FC, Bristol-Myers Squibb Co. 2002 O 2002060386
303. NF-kB inhibitors. Burgess JL, Callahan JF, Wan Z, SmithKline Beecham Corp. 2003 O 2003029242
304. Preparation of ureido-carboxamido thiophene as inhibitors of IKK2 kinase. Griffiths D, Johnstone C, AstraZeneca 2003 O 2003010163
305. Preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2. Baxter A, Brough S, Faull A, Johnstone C, Mcinally T, AstraZeneca, AstraZeneca 2001 O 2001058890
306. Preparation of 2,4-diarylpyridines as IB kinase inhibitors useful as antiinflammatories. Fuchikami K, Ikegami Y, Komura H, Lowinger TB, Masuda T, Murata T, Sakakibara S, Shimada M, Shimazaki M, Shintani T, Umeda M, Yoshida N, Yoshino T, Ziegelbauer KB, Bayer Ag. 2002 O 2002044153
307. Preparation of hydroxyarylpyridines with IB kinase (IKK) inhibiting activity. Fuchikami K, Hiroshi K, Komura H, Koriyama Y, Lowinger TB, Masuda T, Murata T, Sakakibara S, Sato H, Shimada M, Shintani T, Umeda M, Yoshino T, Ziegelbauer KB, Bayer Ag 2002 O 2002024679
308. Discovery of novel and selective IKK- β serine-threonine protein kinase inhibitors. Part 1. Murata T, Shimada M, Sakakibara S, Yoshino T, Kadono H, Masuda T, Shimazaki M, Shintani T, Fuchikami K, Sakai K, Inbe H, Takeshita K, Niki T, Umeda M, Bacon KB, Ziegelbauer KB, Lowinger TB, Bioorg Med Chem Lett 2003 13 913 918
309. Preparation of anilinopyrimidines as IKK inhibitors. Bhagwat SS, Erdman PE, Kois A, Macfarlane KJ, Palanki MSS, Parnes JS, Satoh Y, Signal Pharmaceuticals, Inc 2002 O 2002046171
310. Preparation of optically active pyridooxazinones as antiinflammatory agents. Bacon K, Fuchikami K, Fukushima K, Grosser R, Koriyama Y, Lowinger T, Murata T, Nunami N, Sasaki S, Sato H, Yamauchi M, Yoshino T, Bayer Ag 2003 O 2003076447
311. A method using cyanoguanidine compounds for modulating NFkB activity and use for the treatment of cancer. Madsen MW, Olsen LS, Pharma L 2002 O 2002094265
312. Antitumor drug-cyanoguanidine IKK inhibitor combination. Binderup L, Bramm E, Hamberg KJ, Hjarnaa P-JV, Pharma L 2002 O 2002094322
313. Novel inhibitors of cytokine-induced I κ B α phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME, J Biol Chem 1997 272 21096 21103
314. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, Kawashimo H, Goto T, Taura N, Ichikawa T, Hamasaki K, Nakao K, Umezawa K, Eguchi K, Int J Oncol 2006 29 713 719
315. DHMEQ, a novel NF-{kappa}B inhibitor, enhances anti-tumor activity of taxanes in anaplastic thyroid cancer cells. Meng Z, Mitsutake N, Nakashima M, Starenki D, Matsuse M, Takakura S, Namba H, Saenko V, Umezawa K, Ohtsuru A, Yamashita S, Endocrinology 2008 149 5357 5365
316. Inhibition of lung carcinogenesis and critical cancer-related signaling pathways by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine, indole-3-carbinol and myo-inositol, alone and in combination. Kassie F, Melkamu T, Endalew A, Upadhyaya P, Luo X, Hecht SS, Carcinogenesis 2010 12 1634 1641
317. Modulation of transcription factor NF-kappaB in Hodgkin's lymphoma cell lines: effect of (-)-epicatechin. Mackenzie GG, Oteiza PI, Free Radic Res 2006 40 1086 1094
318. Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. Nicholas C, Batra S, Vargo MA, Voss OH, Gavrilin MA, Wewers MD, Guttridge DC, Grotewold E, Doseff AI, J Immunol 2007 179 7121 7127
319. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Shukla S, Gupta S, Clin Cancer Res 2004 10 3169 3178
320. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. Dai Y, Desano J, Tang W, Meng X, Meng Y, Burstein E, Lawrence TS, Xu L, PLoS One 2010 5 14153
321. Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. Wheeler DS, Catravas JD, Odoms K, Denenberg A, Malhotra V, Wong HR, J Nutr 2004 134 1039 1044
322. Epigallocatechin gallate inhibits phorbol ester-induced activation of NF-kappa B and CREB in mouse skin: role of p38 MAPK. Kundu JK, Surh YJ, Ann N Y Acad Sci 2007 1095 504 512
323. Apigenin, a dietary flavonoid, sensitizes human T cells for activation-induced cell death by inhibiting PKB/Akt and NF-kappaB activation pathway. Xu L, Zhang L, Bertucci AM, Pope RM, Datta SK, Immunol Lett 2008 121 74 83
324. Immunomodulatory activity of xanthohumol: inhibition of T cell proliferation, cell-mediated cytotoxicity and Th1 cytokine production through suppression of NF-kappaB. Gao X, Deeb D, Liu Y, Gautam S, Dulchavsky SA, Gautam SC, Immunopharmacol Immunotoxicol 2009 31 477 484
325. Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-kappaB, degradation of IkappaBalpha, nuclear translocation of p65, and subsequent gene expression. Natarajan K, Manna SK, Chaturvedi MM, Aggarwal BB, Arch Biochem Biophys 1998 352 59 70
326. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Sarkar FH, Li Y, Cancer Metastasis Rev 2002 21 265 280
327. Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. Wang H, Syrovets T, Kess D, Buchele B, Hainzl H, Lunov O, Weiss JM, Scharffetter-Kochanek K, Simmet T, J Immunol 2009 183 4755 4763
328. Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S, Aggarwal BB, Mol Pharmacol 2010 77 818 827
329. Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products. Harikumar KB, Sung B, Tharakan ST, Pandey MK, Joy B, Guha S, Krishnan S, Aggarwal BB, Mol Cancer Res 2010 8 751 761
330. Sesamin inhibits lipopolysaccharide-induced cytokine production by suppression of p38 mitogen-activated protein kinase and nuclear factor-kappaB. Jeng KC, Hou RC, Wang JC, Ping LI, Immunol Lett 2005 97 101 106
331. A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells. Ju W, Wang X, Shi H, Chen W, Belinsky SA, Lin Y, Mol Pharmacol 2007 71 1381 1388
332. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM, Chem Biol 2001 8 759 766
333. In vivo antioxidant treatment suppresses nuclear factor- κ B activation and neutrophilic lung inflammation. Blackwell TS, Blackwell TR, Holden EP, Christman BW, Christman JW, J Immunol 1996 157 1630 1637
334. Vitamin C inhibits NF- κ B activation by TNF via the activation of p38 mitogen-activated protein kinase. Bowie AG, O'Neill LA, J Immunol 2000 165 7180 7188
335. Vitamin C suppresses TNF α -induced NF- κ B activation by inhibiting I κ B α phosphorylation. Carcamo JM, Pedraza A, Borquez-Ojeda O, Golde DW, Biochemistry 2002 41 12995 13002
336. Evidence that reactive oxygen species do not mediate NF- κ B activation. Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, Karin M, Kikugawa K, EMBO J 2003 22 3356 3366
337. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Rasheed Z, Anbazhagan AN, Akhtar N, Ramamurthy S, Voss FR, Haqqi TM, Arthritis Res Ther 2009 11 71
338. Genistein inhibits constitutive and inducible NFkappaB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells. Tabary O, Escotte S, Couetil JP, Hubert D, Dusser D, Puchelle E, Jacquot J, Am J Pathol 1999 155 473 481
339. Regulation of constitutive and induced NF-kappaB activation in malignant melanoma cells by capsaicin modulates interleukin-8 production and cell proliferation. Patel PS, Varney ML, Dave BJ, Singh RK, J Interferon Cytokine Res 2002 22 427 435
340. Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. Syrovets T, Gschwend JE, Buchele B, Laumonnier Y, Zugmaier W, Genze F, Simmet T, J Biol Chem 2005 280 6170 6180
341. Sulforaphane suppresses TNF-alpha-mediated activation of NF-kappaB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3. Moon DO, Kim MO, Kang SH, Choi YH, Kim GY, Cancer Lett 2009 274 132 142
342. Bharangin, a diterpenoid quinonemethide, abolishes constitutive and inducible NF-kB activation by modifying p65 on cysteine 38 residue and inhibiting IkBalpha kinase activation, leading to suppression of NF-kB-regulated gene expression and sensitization of tumor cells to chemotherapeutic agents. Gupta SC, Kannapan R, Hye Kim J, Rahman GM, Francis SK, Raveendran R, Nair MS, Das J, Aggarwal BB, Mol Pharmacol 2011 80 769 781
343. Zerumbone inhibits tumor angiogenesis via NF-kappaB in gastric cancer. Tsuboi K, Matsuo Y, Shamoto T, Shibata T, Koide S, Morimoto M, Guha S, Sung B, Aggarwal BB, Takahashi H, Takeyama H, Oncol Rep 2014 31 57 64
344. Feverfew: chemistry and biological activity. Knight DW, Nat Prod Rep 1995 12 271 276
345. Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. Wen J, You KR, Lee SY, Song CH, Kim DG, J Biol Chem 2002 277 38954 38964
346. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT, Blood 2005 105 4163 4169
347. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Zhang S, Ong CN, Shen HM, Cancer Lett 2004 208 143 153
348. Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. Kim JH, Liu L, Lee SO, Kim YT, You KR, Kim DG, Cancer Res 2005 65 6312 6320
349. Paclitaxel sensitivity of breast cancer cells with constitutively active NF- κ B is enhanced by I κ B α super-repressor and parthenolide. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ Jr, Sledge GW Jr, Nakshatri H, Oncogene 2000 19 4159 4169
350. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB, Mol Pharmacol 2006 69 195 206
351. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, Abubaker J, Platanias LC, Al-Kuraya KS, Uddin S, Mol Cancer Ther 2008 7 3318 3329
352. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL Jr, Brenner DE, Cancer Prev Res (Phila) 2011 4 354 364
353. Is there a role for herbal medicine in the treatment of pancreatic cancer? Highlights from the "44th ASCO Annual Meeting". Chicago IL, USA. May 30-June 3, 2008. Saif MW, JOP 2008 9 403 407
354. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP, Cancer Res 2008 68 7283 7292
355. Targeting proteasomal pathways by dietary curcumin for cancer prevention and treatment. Hasima N, Aggarwal BB, Curr Med Chem 2014 21 1583 1594
356. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM, Science 1997 275 218 220
357. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB, Blood 2007 109 2293 2302
358. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S, Aggarwal BB, Int J Cancer 2010 127 257 268
359. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D, Lattanze J, Franks CF, Zhao S, Ramachandren K, Bylebyl GR, Zhang M, Manthey CL, Petrella EC, Pantoliano MW, Deckman IC, Spurlino JC, Maroney AC, Tomczuk BE, Molloy CJ, Bone RF, J Med Chem 2005 48 909 912
360. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2 -tumor protein 53 protein -protein interaction. Allen JG, Bourbeau MP, Wohlhieter GE, Bartberger MD, Michelsen K, Hungate R, Gadwood RC, Gaston RD, Evans B, Mann LW, Matison ME, Schneider S, Huang X, Yu D, Andrews PS, Reichelt A, Long AM, Yakowec P, Yang EY, Lee TA, Oliner JD, J Med Chem 2009 52 7044 7053
361. Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an α helix. Orner BP, Ernst JT, Hamilton AD, J Am Chem Soc 2001 123 5382 5383
362. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Yin H, Lee GI, Park HS, Payne GA, Rodriguez JM, Sebti SM, Hamilton AD, Angew Chem Int Ed Engl 2005 44 2704 2707
363. Chalcones: an update on cytotoxic and chemoprotective properties. Go ML, Wu X, Liu XL, Curr Med Chem 2005 12 483 499
364. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Stoll R, Renner C, Hansen S, Palme S, Klein C, Belling A, Zeslawski W, Kamionka M, Rehm T, Mühlhahn P, Schumacher R, Hesse F, Kaluza B, Voelter W, Engh RA, Holak TA, Biochemistry 2001 40 336 344
365. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, Shah RB, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang S, Proc Natl Acad Sci USA 2008 105 3933 3938
366. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI888) achieved complete and durable tumor regression in mice. Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, Shargary S, Bernard D, Li X, Zhao T, Zou P, Sun D, Wang S, J Med Chem 2013 56 5553 5561
367. Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: 53/Hdm2 antagonists. Czarna A, Beck B, Srivastava S, Popowicz GM, Wolf S, Huang Y, Bista M, Holak TA, Dömling A, Angew Chem Int Ed 2010 49 5352 5356
368. 3imidazolyl-indoles for the treatment of proliferative diseases. Boettcher A, Buschmann N, Furet P, Groell J, Kallen J, Hergovich LJ, Masuya K, Mayr A, Vaupel A, 2008 O Patent2008119741
369. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency. Hardcastle IR, Liu J, Valeur E, Watson A, Ahmed SU, Blackburn TJ, Bennaceur K, Clegg W, Drummond C, Endicott JA, Golding BT, Griffin RJ, Gruber J, Haggerty K, Harrington RW, Hutton C, Kemp S, Lu X, McDonnell JM, Newell DR, Noble ME, Payne SL, Revill CH, Riedinger C, Xu Q, Lunec J, J Med Chem 2011 54 1233 1243
370. Pyrrolidin-2-ones as hdm2 ligands. Burdack C, Kalinsky C, Ross G, Weber L, Khazak V, Priaxon Ag 2010 O 2010028862
371. Translational approaches targeting the p53 pathway for anti-cancer therapy. Essmann F, Schulze-Osthoff K, Br J Pharmacol 2012 165 328 344
372. Substituted piperidines that increase p53 activity and the uses thereof. Bogen SL, Ma Y, Wang Y, Lahue BR, Nair LG, Shizuka M, Voss ME, Kirova-Snover M, Pan W, Tian Y, Kulkarni BA, Gibeau CR, Liu Y, Scapin G, Rindgen D, Doll RJ, Guzi TJ, Hicklin DJ, Nomeir A, Seide Dugan C, Shipps GW Jr, Maccoss M, 2011 O 2011046771A1
373. Synthesis, in vitro: and in cell studies of a new series of [indoline3,2thiazolidine]-based p53 modulators. Bertamino A, Soprano M, Musella S, Rusciano MR, Sala M, Vernieri E, Di Sarno V, Limatola A, Carotenuto A, Cosconati S, Grieco P, Novellino E, Illario M, Campiglia P, Gomez-Monterrey I, J Med Chem 2013 56 5407 5421
374. A nonpeptidic sulfonamide inhibits the p53mdm2 interaction and activates p53dependent transcription in mdm2overexpressing cells. Galatin PS, Abraham DJ, J Med Chem 2004 47 4163 4165
375. Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development. Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, Chu XJ, Bartkovitz D, Podlaski F, Janson C, Tovar C, Filipovic ZM, Higgins B, Glenn K, Packman K, Vassilev LT, Graves B, J Med Chem 2013 56 5979 5983
376. Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development. Zhang Z, Chu XJ, Liu JJ, Ding Q, Zhang J, Bartkovitz D, Jiang N, Karnachi P, So SS, Tovar C, Filipovic ZM, Higgins B, Glenn K, Packman K, Vassilev L, Graves B, ACS Med Chem Lett 2013 5 124 127
377. An expeditious synthesis of the MDM2-p53 inhibitor AM-8553. Lucas BS, Fisher B, McGee LR, Olson SH, Medina JC, Cheung E, J Am Chem Soc 2012 134 12855 12860
378. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. Sun D, Li Z, Rew Y, Gribble M, Bartberger MD, Beck HP, Canon J, Chen A, Chen X, Chow D, Deignan J, Duquette J, Eksterowicz J, Fisher B, Fox BM, Fu J, Gonzalez AZ, Gonzalez-Lopez De Turiso F, Houze JB, Huang X, Jiang M, Jin L, Kayser F, Liu JJ, Lo MC, Long AM, Lucas B, McGee LR, McIntosh J, Mihalic J, et al. J Med Chem 2014 57 1454 1472
379. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach. Leão M, Pereira C, Bisio A, Ciribilli Y, Paiva AM, Machado N, Palmeira A, Fernandes MX, Sousa E, Pinto M, Inga A, Saraiva L, Biochem Pharmacol 2013 85 1234 1245
380. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction. Zheng GH, Shen JJ, Zhan YC, Yi H, Xue ST, Wang Z, Ji XY, Li ZR, Eur J Med Chem 2014 81C 277 288
381. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G, Nat Med 2002 8 282 288
382. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Zache N, Lambert JM, Wiman KG, Bykov VJ, Cell Oncol 2008 30 411 418
383. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS, Clin Cancer Res 2011 17 2830 2841
384. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ, Cancer Cell 2009 15 376 388
385. Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET. Shalom-Feuerstein R, Serror L, Aberdam E, Muller FJ, van Bokhoven H, Wiman KG, Zhou H, Aberdam D, Petit I, Proc Natl Acad Sci U S A 2013 110 2152 2156
386. APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations. Shen J, van den Bogaard EH, Kouwenhoven EN, Bykov VJ, Rinne T, Zhang Q, Tjabringa GS, Gilissen C, van Heeringen SJ, Schalkwijk J, van Bokhoven H, Wiman KG, Zhou H, Proc Natl Acad Sci U S A 2013 110 2157 2162
387. Targeting the p53 signaling pathway in cancer therapy-the promises, challenges and perils. Stegh AH, Expert Opin Ther Targets 2012 16 67 83
388. Introducing sense into nonsense in treatments of human genetic diseases. Linde L, Kerem B, Trends Genet 2008 24 552 563
389. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. Rowe SM, Clancy JP, BioDrugs 2009 23 165 174
390. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Floquet C, Deforges J, Rousset JP, Bidou L, Nucleic Acids Res 2011 39 3350 3362
391. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G, Nat Med 2004 10 1321 1328
392. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP, Green SR, Cancer Res 2005 65 5399 5407
393. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Choong ML, Yang H, Lee MA, Lane DP, Cell Cycle 2009 8 2810 2818
394. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Smart P, Lane EB, Lane DP, Midgley C, Vojtesek B, Lain S, Oncogene 1999 18 7378 7386
395. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, Tayber O, Hather G, Liu R, Narayanan U, Milhollen MA, Lightcap ES, Cancer Res 2013 73 225 234
396. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, Lane DP, Westwood NJ, Cancer Cell 2008 13 454 463
397. Genome-wide detection and characterization of positive selection in human populations. Sabeti PC, Varilly P, Fry B, Lohmueller J, Hostetter E, Cotsapas C, Xie X, Byrne EH, McCarroll SA, Gaudet R, Schaffner SF, Lander ES, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, et al. Nature 2007 449 913 918
398. Siladenoserinols A-L: new sulfonated serinol derivatives from a tunicate as inhibitors of p53-Hdm2 interaction. Nakamura Y, Kato H, Nishikawa T, Iwasaki N, Suwa Y, Rotinsulu H, Losung F, Maarisit W, Mangindaan RE, Morioka H, Yokosawa H, Tsukamoto S, Org Lett 2012 15 322 325
399. Cancer genes and the pathways they control. Vogelstein B, Kinzler KW, Nat Med 2004 10 789 799
400. Inhibition of encephalomyocarditis virus and poliovirus replication by quinacrine: implications for the design and discovery of novel antiviral drugs. Gasparian AV, Neznanov N, Jha S, Galkin O, Moran JJ, Gudkov AV, Gurova KV, Komar AA, J Virol 2010 84 9390 9397
401. Cancer drug discovery faces the FACT. Draetta GF, Depinho RA, Sci Transl Med 2011 3 95ps34
402. de FACTo nucleosome dynamics. Reinberg D, Sims RJ 3rd, J Biol Chem 2006 281 23297 23301
403. FACT, a factor that facilitates transcript elongation through nucleosomes. Orphanides G, LeRoy G, Chang CH, Luse DS, Reinberg D, Cell 1998 92 105 116
404. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Bruhn SL, Pil PM, Essigmann JM, Housman DE, Lippard SJ, Proc Natl Acad Sci U S A 1992 89 2307 2311
405. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Whittaker SR, Walton MI, Garrett MD, Workman P, Cancer Res 2004 64 262 272
406. Control of formation of two distinct classes of RNA polymerase II elongation complexes. Marshall NF, Price DH, Mol Cell Biol 1992 12 2078 2090
407. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Demidenko ZN, Blagosklonny MV, Cancer Res 2004 64 3653 3660
408. The p53-mdm-2 autoregulatory feedback loop. Wu X, Bayle JH, Olson D, Levine AJ, Genes Dev 1993 7 1126 1132
409. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Marugan JJ, Raboisson P, Schubert C, Koblish HK, Zhao S, Franks CF, Lattanze J, Carver TE, Cummings MD, Maguire D, Grasberger BL, Maroney AC, Lu T, Bioorg Med Chem Lett 2006 16 3310 3314
410. Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Kayali R, Ku JM, Khitrov G, Jung ME, Prikhodko O, Bertoni C, Hum Mol Genet 2012 21 4007 4020